DeepMed Research

Moxifloxacin

Generic Name: Moxifloxacin

Brand Names: Avelox, Moxeza, Vigamox

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₄FN_₃O_₄

CAS Number: 151096-09-2

Unique Ingredient Identifier: U188XYD42P

Background: Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Indication: For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions: Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections

Clinical Trials

Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

Phase 2

Not yet recruiting

Conditions: Mild Spinal Tuberculosis

Interventions: Drug: Rifampin
Drug: Isoniazid
Drug: Rifapentine (RPT)
Drug: Pyrazinamide
Drug: Moxifloxacin
Drug: Ethambutol

First Posted Date: 2025-04-08

Last Posted Date: 2025-04-08

Lead Sponsor: Shandong University

Target Recruit Count: 300

Registration Number: NCT06917495

Locations: 🇨🇳
Shandong Public Health Clinical Center, Jinan, China

A PAN-USR TB Multi-Center Trial

Phase 3

Not yet recruiting

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Bedaquiline (B)
Drug: Sitafloxacin (S)
Drug: Isoniazid (H)
Drug: Linezolid (L)
Drug: Rifampicin (R)
Drug: Moxifloxacin (M)
Drug: Pyrazinamide (Z)
Drug: Pretomanid (Pa)
Drug: Ethambutol (E)

First Posted Date: 2025-04-01

Last Posted Date: 2025-04-01

Lead Sponsor: Shenzhen Third People's Hospital

Target Recruit Count: 610

Registration Number: NCT06905522

A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: BMS-986419 Matching Placebo
Drug: BMS-986419
Drug: Moxifloxacin
Drug: Moxifloxacin Matching Placebo

First Posted Date: 2025-03-25

Last Posted Date: 2025-04-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 74

Registration Number: NCT06846866

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Cardiac Liability Study of Varegacestat in Healthy Participants

Phase 1

Active, not recruiting

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: Moxifloxacin 400 mg
Drug: varegacestat

First Posted Date: 2025-03-03

Last Posted Date: 2025-04-18

Lead Sponsor: Immunome, Inc.

Target Recruit Count: 32

Registration Number: NCT06855264

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: TS-172 20 mg
Drug: TS-172 90 mg
Drug: Moxifloxacin
Drug: Placebo

First Posted Date: 2025-02-20

Last Posted Date: 2025-03-18

Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Target Recruit Count: 52

Registration Number: NCT06837155

Locations: 🇯🇵
Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)

Phase 1

Completed

Conditions: Anesthesia; Adverse Effect
Cardiac Arrhythmia

Interventions: Drug: HSK3486
Drug: Placebo
Drug: Moxifloxacin Hydrochloride

First Posted Date: 2025-01-27

Last Posted Date: 2025-01-30

Lead Sponsor: Haisco-USA Pharmaceuticals, Inc.

Target Recruit Count: 48

Registration Number: NCT06795204

Locations: 🇨🇳
Beijing Gobroad Boren Hospital, Beijing, China

Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery

Phase 4

Completed

Conditions: Cataract
Cystoid Macular Edema After Phacoemulsification

Interventions: Drug: Bromfenac
Drug: Moxifloxacin 0.5% ophthalmic solution
Drug: Dexamethasone phosphate 0.1%

First Posted Date: 2025-01-20

Last Posted Date: 2025-05-06

Lead Sponsor: Inas Abd

Target Recruit Count: 87

Registration Number: NCT06785090

Locations: 🇮🇶
College of Medicine, University of Baghdad, Baghdad, Baghdad Governorate, Iraq

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: BMS-986278
Drug: Moxifloxacin

First Posted Date: 2024-12-24

Last Posted Date: 2025-03-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 42

Registration Number: NCT06746402

Locations: 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States
🇺🇸
Local Institution - 0002, San Antonio, Texas, United States

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

Phase 1

Active, not recruiting

Conditions: Healthy Volunteers - Male and Female

Interventions: Drug: KP-001
Drug: Moxifloxacin 400 mg
Drug: Placebo

First Posted Date: 2024-10-21

Last Posted Date: 2025-04-03

Lead Sponsor: Kaken Pharmaceutical

Target Recruit Count: 40

Registration Number: NCT06649942

Locations: 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States

A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: Moxifloxacin
Drug: Enpatoran low dose
Drug: Enpatoran high dose

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-19

Lead Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Target Recruit Count: 40

Registration Number: NCT06589726

Locations: 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy